




RealRate

PHARMACEUTICAL 2022

Fulcrum Therapeutics Inc.
Rank 213 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

Fulcrum Therapeutics Inc.
Rank 213 of 475



The relative strengths and weaknesses of Fulcrum Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fulcrum Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 108% points. The greatest weakness of Fulcrum Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is -75%, being 202% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	225,998
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,199
Liabilities, Non-Current	0
Other Assets	1,634
Other Compr. Net Income	-395
Other Expenses	0
Other Liabilities	4,262
Other Net Income	207
Property and Equipment	7,368
Research and Development	69,701
Revenues	19,163
Selling, General and Administrative Expense	30,516

Output Variable	Value in 1000 USD
Assets	235,000
Liabilities	23,461
Expenses	100,217
Stockholders Equity	211,539
Net Income	-80,847
Comprehensive Net Income	-81,044
Economic Capital Ratio	-75%

